Seelos Therapeutics to Participate in Two Investor Conferences in September
09/09/2021 - 08:00 AM
NEW YORK , Sept. 9, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference on September 22 nd and the Cantor Virtual Global Healthcare Conference, September 27 th -30th , 2021.
M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference
Raj Mehra, Ph.D., Chairman and CEO will participate in a Depression Panel titled: "Spravato opened the door, what comes next?", on Wednesday, September 22 nd at 2:00pm ET . The panel discussion will be moderated by Jason McCarthy , Ph.D., Head of Biotechnology Research at Maxim Group. For conference registration: https://m-vest.com/events/advances-in-mental-health Cantor Virtual Global Healthcare Conference
Raj Mehra, Ph.D., Chairman and CEO, will participate in a fireside chat on Wednesday, September 29 th at 10:00am ET and host 1x1 meetings via conference calls. The fireside chat will be moderated by Charles C. Duncan , Ph.D., Senior Biotechnology Analyst at Cantor Fitzgerald. For webcast link and replay: https://wsw.com/webcast/cantor12/seel/2075290 About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.
Contact Information:Anthony Marciano New York, NY 10022anthony.marciano@seelostx.com https://seelostherapeutics.com/ https://twitter.com/seelostx https://www.linkedin.com/company/seelos
https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-in-september-301371732.html
SOURCE Seelos Therapeutics, Inc.
SEEL Rankings
#5248 Ranked by Stock Gains
SEEL Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Pharmaceuticals: Other, Biotechnology, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
New York
About SEEL
seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a
